The authors evaluated the role of Celecoxib, an inhibitor of Prostaglandin E(2) (PGE(2)), which is a potent immune modulator in the treatment of urothelial cancer. PGE(2) is known to suppress both tumour antigen-specific helper T (T(H)1) cells and the generation of cytotoxic T lymphocytes (CTLs).


Fatal error: Call to undefined function is_syndicated() in /home/meddisco/public_html/wp-content/themes/executive-pro/single.php on line 32